Literature DB >> 21378247

Low serum citrulline concentration correlates with catheter-related bloodstream infections in children with intestinal failure.

Melissa A Hull1, Brian A Jones, David Zurakowski, Bram Raphael, Clifford Lo, Tom Jaksic, Christopher Duggan.   

Abstract

BACKGROUND: Serum citrulline concentration is used as a biomarker of enterocyte mass and enteral tolerance, and low serum concentrations are correlated with bacteremia in immunosuppressed adults undergoing hematopoietic stem cell transplant. The authors sought to determine if citrulline was associated with the development of catheter-related bloodstream infections (CRBSIs) in children with intestinal failure.
METHODS: Data were reviewed from 66 children treated in a multidisciplinary intestinal rehabilitation program, who had serum concentration citrulline measured between January 2007 and August 2009. All patients had a diagnosis of intestinal failure requiring parenteral nutrition (PN) support. Exclusion criteria included central venous catheter in situ <30 days, creatinine clearance <20 mL/minute, or a history of organ transplant/immunosuppression.
RESULTS: A total of 15 patients were excluded because of the above criteria. In this cohort of 51 patients, 26 (51%) developed CRBSIs. Both groups were similar in terms of gestational age, diagnosis, nutrition status, and biochemical liver function tests. The mean (± standard deviation [SD]) minimum serum citrulline concentration was significantly lower in patients who developed CRBSIs (6.7 ± 4.6 µmol/L) than in those who did not (11.3 ± 6.4 µmol/L, P = .004). Multivariate logistic regression analysis identified lower minimum serum citrulline concentration and longer central venous catheter duration as independently associated with CRBSI (P = .003 and P = .038, respectively).
CONCLUSIONS: Low serum citrulline concentration and longer central venous catheter time are independently associated with CRBSI in children with intestinal failure. Serum citrulline concentration may be a useful biomarker to identify patients with intestinal failure who are at high risk of developing a CRBSI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21378247      PMCID: PMC3366263          DOI: 10.1177/0148607110381406

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  39 in total

1.  Plasma arginine and citrulline concentrations in critically ill children: strong relation with inflammation.

Authors:  Dick A van Waardenburg; Carlijn T de Betue; Yvette C Luiking; Monique Engel; Nicolaas E Deutz
Journal:  Am J Clin Nutr       Date:  2007-11       Impact factor: 7.045

2.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

Authors:  Teresa C Horan; Mary Andrus; Margaret A Dudeck
Journal:  Am J Infect Control       Date:  2008-06       Impact factor: 2.918

Review 3.  Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction.

Authors:  Pascal Crenn; Bernard Messing; Luc Cynober
Journal:  Clin Nutr       Date:  2008-04-28       Impact factor: 7.324

Review 4.  Bacterial translocation: overview of mechanisms and clinical impact.

Authors:  Silvio Balzan; Claudio de Almeida Quadros; Roberto de Cleva; Bruno Zilberstein; Ivan Cecconello
Journal:  J Gastroenterol Hepatol       Date:  2007-04       Impact factor: 4.029

5.  Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation.

Authors:  Cinzia Papadia; Roy A Sherwood; Chrysostomos Kalantzis; Katharina Wallis; Umberto Volta; Erica Fiorini; Alastair Forbes
Journal:  Am J Gastroenterol       Date:  2007-04-24       Impact factor: 10.864

6.  Effect of lactulose on bacterial translocation and intestinal adaptation in a rat model of short bowel syndrome.

Authors:  Igor Sukhotnik; Isaac Srugo; Jorge G Mogilner; Michael Lurie; Arnold G Coran; Ron Shaoul
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-05       Impact factor: 2.839

7.  Canadian home total parenteral nutrition registry: preliminary data on the patient population.

Authors:  Maitreyi Raman; Leah Gramlich; Scott Whittaker; Johane P Allard
Journal:  Can J Gastroenterol       Date:  2007-10       Impact factor: 3.522

Review 8.  Biomarkers for radiation-induced small bowel epithelial damage: an emerging role for plasma Citrulline.

Authors:  Ludy Lutgens; Philippe Lambin
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

9.  Infectious port complications are more frequent in younger patients with hematologic malignancies than in solid tumor patients.

Authors:  Panagiotis Samaras; Stefan Dold; Julia Braun; Peter Kestenholz; Stefan Breitenstein; Alexander Imhof; Christoph Renner; Frank Stenner-Liewen; Bernhard C Pestalozzi
Journal:  Oncology       Date:  2008-08-21       Impact factor: 2.935

10.  Early central catheter infections may contribute to hepatic fibrosis in children receiving long-term parenteral nutrition.

Authors:  Dominique Hermans; Cécile Talbotec; Florence Lacaille; Olivier Goulet; Claude Ricour; Virginie Colomb
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-04       Impact factor: 2.839

View more
  9 in total

1.  Free amino acid composition of saliva in patients with healthy periodontium and periodontitis.

Authors:  Nur Balci; Şivge Kurgan; Ali Çekici; Tülin Çakır; Muhittin A Serdar
Journal:  Clin Oral Investig       Date:  2021-05-11       Impact factor: 3.573

2.  Serum citrulline as a biomarker of gastrointestinal function during hematopoietic cell transplantation in children.

Authors:  Kerri B Gosselin; Henry A Feldman; Andrew L Sonis; Lori J Bechard; Mark D Kellogg; Kathleen Gura; Robert Venick; Catherine M Gordon; Eva C Guinan; Christopher Duggan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-06       Impact factor: 2.839

3.  Central line-associated bloodstream infections in neonates with gastrointestinal conditions: developing a candidate definition for mucosal barrier injury bloodstream infections.

Authors:  Susan E Coffin; Sarah B Klieger; Christopher Duggan; W Charles Huskins; Aaron M Milstone; Gail Potter-Bynoe; Bram Raphael; Thomas J Sandora; Xiaoyan Song; Danielle M Zerr; Grace M Lee
Journal:  Infect Control Hosp Epidemiol       Date:  2014-10-02       Impact factor: 3.254

4.  Reduced plasma citrulline levels in low birth weight infants with necrotizing enterocolitis.

Authors:  Istemi Han Celik; Gamze Demirel; Fuat Emre Canpolat; Ugur Dilmen
Journal:  J Clin Lab Anal       Date:  2013-07       Impact factor: 2.352

Review 5.  Medical update and potential advances in the treatment of pediatric intestinal failure.

Authors:  Nader N Youssef; Adam G Mezoff; Beth A Carter; Conrad R Cole
Journal:  Curr Gastroenterol Rep       Date:  2012-06

6.  Necrotizing enterocolitis is associated with earlier achievement of enteral autonomy in children with short bowel syndrome.

Authors:  Eric A Sparks; Faraz A Khan; Jeremy G Fisher; Brenna S Fullerton; Amber Hall; Bram P Raphael; Christopher Duggan; Biren P Modi; Tom Jaksic
Journal:  J Pediatr Surg       Date:  2015-10-23       Impact factor: 2.545

7.  Markers of Environmental Enteric Dysfunction Are Associated With Neurodevelopmental Outcomes in Tanzanian Children.

Authors:  Analee J Etheredge; Karim Manji; Mark Kellogg; Hao Tran; Enju Liu; Christine M McDonald; Rodrick Kisenge; Said Aboud; Wafaie Fawzi; David Bellinger; Andrew T Gewirtz; Christopher P Duggan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-06       Impact factor: 2.839

8.  Nutritional therapy complications in children with ultra-short bowel syndrome include growth deficiency but not cholestasis.

Authors:  Katarzyna Olszewska; Janusz Ksiazyk; Dariusz Kozlowski; Magdalena Pajdowska; Malgorzata Janusz; Maciej Jaworski
Journal:  Acta Paediatr       Date:  2018-02-27       Impact factor: 2.299

Review 9.  Biomarkers of sepsis: time for a reappraisal.

Authors:  Charalampos Pierrakos; Dimitrios Velissaris; Max Bisdorff; John C Marshall; Jean-Louis Vincent
Journal:  Crit Care       Date:  2020-06-05       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.